Latest Oncology News

Orca-T Reduces GVHD, Improves GVHD-Free RFS in Posttransplant Setting Across Hematologic Cancers

Orca-T Reduces GVHD, Improves GVHD-Free RFS in Posttransplant Setting Across Hematologic Cancers

January 28th 2022

Gina Mauro

Arpita Gandhi, MD, discusses the background of Orca-T in further detail and how this type of treatment could revolutionize outcomes for patients with serious hematologic malignancies.

Active Clinical Trials of Interest in Endometrial Cancer Explore Novel Up-Front Approaches

Active Clinical Trials of Interest in Endometrial Cancer Explore Novel Up-Front Approaches

January 27th 2022

Ryan Scott

Bradley R. Corr, MD, discusses practice-changing developments and active clinical trials that are being done in endometrial cancer.

Modest Budget Effects Demonstrate Promise for Uptake of Genomic Profiling in NSCLC

Modest Budget Effects Demonstrate Promise for Uptake of Genomic Profiling in NSCLC

January 27th 2022

Brittany Lovely

The identification of actionable oncogenetic drivers in patients with non–small cell lung cancer affords clinicians the opportunity to use targeted agents to optimize outcomes.

2-Year OS Improves Over 20 Years in Relapsed Ph+ ALL Post Allogeneic Transplant

2-Year OS Improves Over 20 Years in Relapsed Ph+ ALL Post Allogeneic Transplant

January 27th 2022

Caroline Seymour

The 2-year overall survival rate almost doubled between 2000 and 2004 and 2015 and 2019 in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia who had relapsed after allogeneic hematopoietic cell transplant, indicating improvements in patient care overall.

Sorting Through Sexism, Guilt, and Motherhood in Medicine

Sorting Through Sexism, Guilt, and Motherhood in Medicine

January 27th 2022

OncLive Staff

Drs Garg, Outlaw-Evans, and Farrington discuss their experiences as women in oncology, changes they have observed in the culture of medicine, and their advice to young women entering the field.

Latest Oncology Videos

All Oncology News

Trilaciclib Reduces Need for G-CSF, RBC Transfusions From Chemo-Induced AEs in ES-SCLC

October 19th 2020

Gina Mauro

Treatment with the CDK4/6 inhibitor trilaciclib prior to chemotherapy compared with placebo significantly reduced the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer.

FDA Grants Priority Review to Nivolumab Plus Cabozantinib in Advanced RCC

October 19th 2020

Kristi Rosa

The FDA has granted a priority review designation to a supplemental biologics license application and supplemental new drug application for nivolumab plus cabozantinib for the treatment of patients with advanced renal cell carcinoma.

FIP200 Deletion May Enhance Response to Immunotherapy in Breast Cancer

October 19th 2020

Hayley Virgil

FIP200 deletion was found to enhance the efficacy of immune checkpoint inhibition in patients with nonresponsive breast cancer.

Pediatric Osteosarcoma Harbors a High Incidence of Pathogenic TP53 Variants

October 19th 2020

Caroline Seymour

TP53 was found to be the only gene with a germline de novo pathogenic or likely pathogenic variant in pediatric patients with osteosarcoma.

DisTinGuish Trial Doses First Patient With Investigational Dickkopf-1 Antibody DKN-01 Plus Tislelizumab in Gastric/GEJ Cancer

October 19th 2020

Hayley Virgil

The first patient has officially been dosed with investigational anti-Dickkopf-1 antibody plus tislelizumab with or without chemotherapy as part of the ongoing phase 2a DisTinGuish study (NCT04363801) in patients with gastric or gastroesophageal junction cancer.

Investigators Tackle New NSCLC Target With Glutaminase Inhibitor

October 19th 2020

Denise Myshko

Telaglenastat, a novel drug that targets a key metabolic pathway, has shown encouraging antitumor activity in several cancer types.

IDE196/Crizotinib Combo Under Exploration in GNAQ/11+ Solid Tumors

October 18th 2020

Jessica Hergert

An ongoing, collaborative clinical trial has been expanded to evaluate the investigational protein kinase C inhibitor IDE196 in combination with the multikinase inhibitor crizotinib (Xalkori) for patients with GNAQ- or GNA11-mutated solid tumors, including metastatic uveal melanoma , skin melanoma, lung cancer, and colorectal cancer.

Community-Based Oncology Practices Adapt to Uncertainty of Pandemic

October 17th 2020

Amy Valley, PharmD

The impact of COVID-19 has been felt deeply by community-based oncologists.

KTE-X19 Granted Positive EU Opinion for Relapsed/Refractory MCL

October 16th 2020

Kristi Rosa

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for KTE-X19 as a treatment in adult patients with relapsed/refractory mantle cell lymphoma who previously received 2 or more lines of systemic therapy, including a BTK inhibitor.

NICE Recommends Isatuximab Plus Pomalidomide/Dexamethasone for Relapsed/Refractory Myeloma

October 16th 2020

Kristi Rosa

The United Kingdom’s National Institute for Health and Care Excellence has recommended isatuximab-irfc in combination with pomalidomide and dexamethasone as a treatment option for select patients with relapsed/refractory multiple myeloma.

Dr. Mesa on the Rationale for the Earlier Use of Ruxolitinib in Myelofibrosis

October 16th 2020

Ruben Mesa, MD

Ruben A. Mesa, MD, discusses the rationale for the earlier use of ruxolitinib in myelofibrosis.

Dr. Silbermann on the CASTOR Trial in Relapsed/Refractory Myeloma

October 16th 2020

Rebecca Silbermann, MD, MMS

Rebecca Silbermann, MD, MMS, discusses the phase 3 CASTOR trial in relapsed/refractory multiple myeloma.

Dr. McDermott on the Design of the DASL-HiCAP Trial in High-Risk Prostate Cancer

October 16th 2020

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the design of the DASL-HiCAP trial in high-risk prostate cancer.

Dr. O’Regan on the Role of Therapy Escalation in HER2+ Breast Cancer

October 16th 2020

Ruth M. O'Regan, MD

Ruth O’Regan, MD, discusses the role of therapy escalation in HER2-positive breast cancer.

Dr. Pautier on Results of the LMS-02 Trial in Uterine and Soft Tissue Sarcomas

October 16th 2020

Patricia Pautier, MD

Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in ​uterine and soft tissue leiomyosarcoma.

See All News